NCT05335499View on ClinicalTrials.gov

A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria

PHASE2CompletedINTERVENTIONAL

Enrollment

126

Participants

Timeline

Start Date

June 28, 2022

Primary Completion Date

December 22, 2023

Study Completion Date

December 22, 2023

Conditions

Chronic Spontaneous Urticaria

Interventions

DRUG

TAS5315 Dose 1

Treatment period: oral administration for 12 weeks, QD

DRUG

TAS5315 Dose 2

Treatment period: oral administration for 12 weeks, QD

DRUG

TAS5315 Dose 3

Treatment period: oral administration for 12 weeks, QD

DRUG

TAS5315 Dose 4

Treatment period: oral administration for 12 weeks, QD

DRUG

TAS5315 Dose 5

Treatment period: oral administration for 12 weeks, QD

DRUG

Placebo

"* Screening period: oral administration for 2 weeks, QD~* Treatment period: oral administration for 12 weeks, QD"

Trial Locations (12)

Unknown

A site selected by Taiho Pharmaceutical Co., Ltd., Ehime

A site selected by Taiho Pharmaceutical Co., Ltd., Fukuoka

A site selected by Taiho Pharmaceutical Co., Ltd., Gunma

A site selected by Taiho Pharmaceutical Co., Ltd., Hiroshima

A site selected by Taiho Pharmaceutical Co., Ltd., Ishikawa

A site selected by Taiho Pharmaceutical Co., Ltd., Kagawa

A site selected by Taiho Pharmaceutical Co., Ltd., Kumamoto

A site selected by Taiho Pharmaceutical Co., Ltd., Obihiro

A site selected by Taiho Pharmaceutical Co., Ltd., Osaka

A site selected by Taiho Pharmaceutical Co., Ltd., Sapporo

A site selected by Taiho Pharmaceutical Co., Ltd., Tokyo

A site selected by Taiho Pharmaceutical Co., Ltd., Yokohama

All Listed Sponsors

lead

Taiho Pharmaceutical Co., Ltd.

INDUSTRY